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Zusammenfassung
Hintergrund: Störungen der respiratorischen Adaptation 
bei Geburt sind Hauptgründe für die Aufnahme von Neu-
geborenen auf die Intensivstation und die Trennung von 
ihren Müttern. Damit sind potenziell langfristige Folgen 
für die Mutter-Kind-Interaktion sowie die Langzeitent-
wicklung des Kindes verbunden. Es besteht ein dringen-
der Bedarf an wirksamen präventiven und therapeuti-
schen Maßnahmen zur Behandlung dieses häufigen Pro-
blems. Fallbericht: Wir berichten über 2 Fälle von Neuge-
borenen mit respiratorischer Adaptationsstörung, die 
auf der Grundlage von pathophysiologischen Überle-
gungen und auf besonderen Wunsch der Eltern off-label 
mit dem anthroposophischen Medikament Pulmo/Vivianit 
comp. behandelt wurden. In beiden Fällen konnte ein un-
mittelbares und nachhaltiges Ansprechen ohne uner-
wünschte Wirkungen dokumentiert werden. Schluss­
folgerung: Dieser neue therapeutische Ansatz verdient 
weitere Aufmerksamkeit in der klinischen Forschung, er 
kann aber erst dann für die Routineanwendung empfoh-
len werden, wenn höhere Evidenz verfügbar ist.
Keywords
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Summary
Background: Disorders of the respiratory transition at 
birth are major reasons for neonates being admitted to 
intensive care units and separated from their mothers. 
This has potential long-lasting consequences for the 
mother-infant interaction as well as the long-term devel-
opment of the child. There is an urgent need for effective 
preventive and therapeutic measures for this frequent 
disorder. Case Report: We report the cases of 2 newborn 
infants with respiratory transitional disorder treated off-
label with the anthroposophic medicament Pulmo/Vivi-
anit comp. based on pathophysiological considerations 
and on particular parental request. In both cases, an im-
mediate and sustainable response could be documented 
without adverse effects. Conclusion: This new therapeu-
tic approach merits further attention in clinical research 
but cannot be recommended for routine practice before 
more high-level evidence is available.
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Introduction
Postpartum separation of the mother and her baby affects the 
maternal attachment, breastfeeding and the physiological adapta-
tion of both the mother and the newborn infant [1]. A randomized 
controlled trial demonstrated detrimental effects of an early mother- 
infant separation on the mother-infant interaction even 1 year later 
[2]. Therefore, future strategies should focus on keeping mother 
and baby together and on reducing separation due to medical rea-
sons during the neonatal period to a minimum.
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Acute respiratory disorders are major reasons for neonates 
being separated from their mothers and admitted to the neonatal 
intensive care unit (NICU) after birth. In particular, neonates de-
livered by elective caesarean section have an increased risk of res-
piratory morbidity [3]. The current management mainly focuses 
on respiratory support, while no effective pharmacological treat-
ment specifically promoting the functional changes of the respira-
tory transition could be established so far [4].
In addition to potential consequences for the mother-infant in-
teraction, neonatal respiratory disorders are a risk factor for the 
long-term development of the child either due to the disease itself 
or due to complications of the intensive care management [5]. The 
frequency of these disorders as well as the associated economic 
burden for the health care systems warrants research for new ther-
apeutic approaches helping to avoid or shorten the NICU hospi-
talization. This should not be restricted to already known pharma-
ceutical products but should cover all fields, including integrative 
and complementary medicine.
We report 2 cases of respiratory transitional disorder following 
caesarean section. Both infants were treated off-label with the an-
throposophic medication Pulmo/Vivianit comp. (WALA® Heil-
mittel GmbH, Bad Boll/Eckwälden, Germany) and mother-infant 
separation could be avoided. This treatment trial was made possi-
ble due to the explicit request and consent of the parents and be-
cause of the particular hospital setting with continuous monitor-
ing in the well-baby nursery and a complete NICU backup in the 
same unit.
Pulmo/Vivianit comp. was originally developed for the treat-
ment of pneumonia [6]. It is composed of 4 constituents, with nor-
mal saline serving as solvent: the minerals Tartarus stibiatus D7 
and Vivianite D7, the plant Bryonia cretica D5, and the animal 
organ preparation Pulmo D16 of a bovine lung. Each of the poten-
tized components and the final composition of the product are 
prepared according to the anthroposophic pharmaceutical codex, 
which guarantees good manufacturing practice and pharmaceuti-
cal safety issues [7]. The medication is officially registered and li-
censed by the respective regulatory bodies in Germany (Federal 
Institute for Drugs and Medical Devices) and Switzerland (Swiss-
medic). The therapeutic properties are attributed to the stimula-
tion of lung development and regeneration, regulation of the pul-
monary fluid balance, and the coordination of lung ventilation and 
perfusion optimizing gas exchange [6, 8].
Scientific evidence for Pulmo/Vivianit comp. is limited to ex-
pert opinions and case reports [8–11]. These suggest effectiveness 
in the treatment of pulmonary disorders in children and adults 
without indication of adverse effects or safety problems. As these 
disorders comprise pathophysiologic alterations on a functional 
level comparable to the transitional changes during pulmonary ad-
aptation at birth, we hypothesized a possible effect of Pulmo/Vivi-
anit comp. in the treatment of neonatal respiratory transitional 
disorders.
Case Reports
Case 1
A newborn girl had persistent signs of respiratory distress at the age of 8 h. 
The pregnancy, the delivery by caesarean section at gestational week 39 4/7 be-
cause of breech presentation, and the primary adaptation were uneventful (um-
bilical artery pH 7.30, Apgar 9/10/10, birth weight 3,540 g). On examination, 
she was laying in prone position in skin-to-skin contact on the mother’s chest. 
Leading symptoms were loud grunting, nasal flaring, and subcostal retractions. 
The respiratory rate and oxygen saturation (SpO2) without supplemental oxy-
gen were normal. The baby was awake, but her eyes were closed and no sponta-
neous movements despite increased work of breathing could be observed. 
There was no further indication of perinatal infection.
Assuming respiratory distress following delayed pulmonary transition after 
caesarean section, an attempt was made to specifically support the respiratory 
transition with Pulmo/Vivianit comp. This could be performed immediately 
without separating the baby from the mother. The solution was administered 
orally 3 times 5 drops at 5-min intervals. Beginning already 1 min after the first 
application, the signs of respiratory distress improved continuously and ceased 
completely after 15 min.
Because of this rapid and complete recovery there was no need for further 
investigations and the baby could stay with the mother. Under close monitor-
ing, no relapse of respiratory distress and no adverse treatment events occurred 
until discharge on day 5. In retrospect, the parents were satisfied and grateful 
that the respiratory disorder after birth could be resolved without separation of 
mother and baby and without painful (blood sampling) or harmful (radio-
graphic imaging) investigations of their child.
Case 2
Twin boys were delivered by caesarean section at the gestational age of 35 
5/7 weeks, after premature rupture of membranes of the leading twin. There 
were no signs or risk factors of perinatal infection. The birth weight was 2,450 
and 2,350 g, Apgar was 8/9/10 and 7/8/9, and the umbilical artery pH was 7.22 
and 7.21, respectively.
Only the second twin showed progressive signs of respiratory distress with 
strong grunting, nasal flaring, subcostal retractions, tachypnea and need for 
supplemental oxygen (fraction of inspired oxygen (FiO2) maximum 0.45) due 
to a persistent low SpO2 around 80% under room air at the age of 10 min. Apart 
from the respiratory disorder, other vital signs and a complete physical exami-
nation were normal. The respiratory disorder persisted to the age of 30 min and 
a decision had to be made concerning transfer of the boy to the NICU for con-
tinuous respiratory support and monitoring.
In this situation, a therapeutic trial was made to support the infant’s own 
effort in managing the respiratory transition. Pulmo/Vivianit comp. was given 
orally 3 times 5 drops at 5-min intervals. An immediate response with gradual 
improvement of the respiratory symptoms could be observed within minutes. 
The grunting decreased and stopped intermittently; the SpO2 increased to val-
ues above 96% even after reducing the FiO2 to finally 0.21 (room air). 20 min 
after the first dose of Pulmo/Vivianit comp., only a tachypnea of 80/min (refer-
ence range 40–60/min) persisted as a residual finding of the respiratory distress. 
Thus, clinical observation with monitoring of the SpO2 and respiratory symp-
toms gave sufficient information and further diagnostic tests could be omitted. 
At the age of 2 h, breathing had normalized and a transfer of both twins to-
gether with their mother to the well-baby nursery was possible. The regular 
controls following premature birth were completely normal, without indication 
of respiratory problems or adverse reactions until discharge after 1 week.
Discussion
Both cases are highly representative of postnatal respiratory dis-
tress caused by an impaired respiratory transition from intrauter-
ine to extrauterine life [4, 12]. The treatment was performed only 
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with Pulmo/Vivianit comp., and an immediate effect could be ob-
served. The pattern of improvement corresponded exactly to the 
natural course of delayed respiratory transition, with increased 
work of breathing at the beginning and tachypnea only at the end 
of the symptomatic period. Yet, following the application of 
Pulmo/Vivianit comp., the duration of the respiratory disorder was 
markedly reduced and an admission to the NICU with consecutive 
separation from the mother could be avoided. Along with the res-
piratory improvement, both infants became more active and inter-
active, regular movements were established, feeding and digestive 
functions improved, and normal diuresis started. Finally, no ad-
verse effects of the treatment occurred in both cases.
Case reports provide a low level of evidence as assessment and 
generalizability of the observed treatment effect are limited. How-
ever, to distinguish it from a spontaneous recovery and to judge on 
the probability of a true association between the therapeutic inter-
vention and the observed outcome in our cases, some criteria can 
be stated: (1) the duration and severity of the respiratory disorder 
and its relation to the timing of the response with prompt and 
marked improvement within minutes, (2) the absence of co-inter-
ventions, (3) long-lasting normalization of respiration and the 
overall functional state of the babies, (4) consistency among both 
cases, (5) the specific and predicted outcome following the inter-
vention, and finally (6) the confirmation of the idea of specifically 
supporting the infants’ own regulative forces in managing the dis-
order by the fact that the observable development after the medica-
tion resembles exactly the natural course of the disease, albeit in an 
accelerated mode. One needs to keep in mind that all currently es-
tablished therapies started with single case reports, sometimes 
even before the pharmacological mechanisms of action had been 
discovered.
The need for research on preventive and therapeutic interven-
tions covers pharmaceutical agents stimulating the transitional 
changes in the respiratory system at birth. This includes glucocorti-
coids, inhaled epinephrine, inhaled salbutamol, diuretics, and oral 
or aerosolized furosemide [4]. Despite promising concepts, none of 
these agents achieved sufficient evidence from clinical trials to gain 
access to routine clinical practice. According to the encouraging re-
sults presented here, the treatment of respiratory transitional disor-
ders with Pulmo/Vivianit comp. merits further attention in clinical 
practice and research. It is based on the physiology of the respira-
tory transition and its disorders on a functional level [12]. It could 
help to avoid admission and separation of affected neonates as well 
as complement the conventional respiratory support in the NICU 
in order to reduce the morbidity and mortality of this frequent dis-
order. Currently, the treatment of respiratory transitional disorders 
in newborns with Pulmo/Vivianit comp. should be considered ex-
perimental. More high-level evidence research is warranted before 
it can be recommended for routine practice in neonatology. In ad-
dition, further controlled studies should not only focus on effective-
ness but also on safety issues in this vulnerable population.
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